A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies.
This study is designed to investigate the safety and tolerability of a new drug, AZD5363, in
patients with advanced cancer - and to identify a dose and schedule that can be used in the
future. This study will also investigate how the body handles AZD5363 (ie, how quickly the
body absorbs and removes the drug). This study will also investigate anti-tumour activity of
AZD5363 in patients with advanced / metastatic breast, gynaecological cancers or other solid
cancers bearing either AKT1 / PIK3CA or PTEN mutation.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society